[International multicentre studies, inter-cohort analyses, unsustainable proliferation of authorship. Are these the expected answers to face HIV disease?].
The most recent evidences on HIV infection have been obtained through large multicentre trials, or intercohort analyses including patients enrolled by hundreds of investigators-coinvestigators around the world. While extensively pooled data are needed to assess infrequent events (proportionally rare toxicity), long-term end-points (like mortality), or to perform efficacy or non-inferiority comparisons between different therapeutic strategies, relevant biases-distorsions descending from the extremely elevated number of enrolling centers and sperimentators are expected, while the full report among quoted co-authors of all investigators and co-investigators supports an unacceptable number of presumptive authors of each paper, ranging from hundreds to over one thousand.
Manfredi
Roberto
R
Divisione di Malattie Infettive, Dipartimento di Medicina Interna, dell'Invecchiamento e Malattie Nefrologiche, Alma Mater Studiorum Università di Bologna, Policlinico S. Orsola-Malpighi, Bologna. roberto.manfredi@unibo.it
D044966:Anti-Retroviral Agents / Q000627:therapeutic use*; D001319:Authorship; D015982:Bias; D015331:Cohort Studies; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic
D044966:Anti-Retroviral Agents